Actively Recruiting
The Voice as a Tool to Detect Recurrence of Laryngeal and Hypopharyngeal Cancer
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2025-07-29
100
Participants Needed
2
Research Sites
151 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators will obtain three-monthly voice recordings and fiberendoscopic examinations of the larynx/hypopharynx for a minimal period of 6 months from all laryngeal/hypopharyngeal squamous cell carcinoma (LSCC/HPSCC) patients, who have successfully completed curative primary treatment, except those who underwent total laryngectomy. Furthermore, the investigators will ask the patients to fill out the voice handicap index-30 questionnaire (VHI-30) during each study visit. The VHI-30 allows to make a subjective assessment of the patients' own vocal problem. The primary objective is to assess the feasibility and compliance of longterm regular voice monitoring in LSCC and HPSCC follow-up.
CONDITIONS
Official Title
The Voice as a Tool to Detect Recurrence of Laryngeal and Hypopharyngeal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histopathologically confirmed carcinoma in-situ or invasive laryngeal or hypopharyngeal squamous cell carcinoma
- Age 18 years or older
- Completed curative treatment by any method
- Clinical confirmation of complete remission of the cancer through ENT examination including fiberendoscopy at enrollment (6 to 30 months after treatment)
- Informed consent signed by the participant
- Patients with certain non-laryngeal/hypopharyngeal malignant tumors in remission and life expectancy of at least 6 months are eligible
- Patients with treated skin squamous cell carcinoma or basal cell carcinoma within 6 months before enrollment are eligible
You will not qualify if you...
- History of total laryngectomy as primary therapy
- Any local, regional, or systemic persistence, progression, or recurrence of laryngeal or hypopharyngeal cancer before enrollment
- Tumor persistence, progression, or recurrence of other related malignant tumors within 6 months before enrollment
- Previously treated laryngeal or hypopharyngeal cancer or second primary malignancies before the studied cancer
- Medical, psychological, family, social, or geographic conditions that may affect study compliance
- Inability to follow study procedures or insufficient knowledge of German or French language
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Inselspital, Bern University Hospital
Bern, Switzerland, 3010
Actively Recruiting
2
Department of Oto-Rhino-Larnygology, Head and Neck Surgery, University Hospital Zurich
Zurich, Switzerland, 8091
Actively Recruiting
Research Team
R
Roland Giger, Prof.
CONTACT
M
Miranda Visini, Dr. med.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here